子宮内膜がんにおけるセンチネルリンパ節生検 (ENDO-3)
明らかな初期段階の子宮内膜がんにおける後腹膜リンパ節郭清なしのセンチネルリンパ節生検を比較する第 III 相ランダム化臨床試験
Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC typically includes removal of the uterus and to determine the extent of the disease (removal of fallopian tubes, ovaries & if required a lymph node dissection (surgical staging)). While lymph node dissection may be valuable to guide the need for adjuvant treatment (chemo or radiotherapy) after surgery, it has been a topic of controversy for the last 30 years. In some patients it causes morbidity, specifically lymphoedema. This recently has been replaced with sentinel node biopsy (SNB). It requires an injection of a dye into the cervix with specific equipment & surgical dissection of the lymph node in which the dye first becomes visible. Despite this promising proposition & similar to a lymph node dissection, the value to patients, cost effectiveness & potential harms (e.g. lymphedema) of SNB compared to no-node dissection in EC has never been established. Aim: determine the value of SNB for patients, the healthcare system and exclude detriment to patients using a randomised approach 1:1. Stage 1 - 444 patients. Stage 2 additional 316 patients.
Primary Outcome Stage 1:
Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities.
Primary Outcome Stage 2:
Treatment non-inferiority as evaluated by disease-free survival status at 4.5 years post-surgery, as measured by the time interval between the date of randomisation and date of first recurrence. Confirmation of recurrent disease will be ascertained through clinical assessment, radiological work-up and/or histological results.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
- 手順:TH BSO with SNB Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
- 手順:TH BSO without retroperitoneal node dissection Note: If participants (≤45yo), Grade 1 endometrial adenocarcinoma with myometrial invasion <50%, wish to retain their ovaries a BSO may be omitted
詳細な説明
Hypothesis: The primary hypothesis is that SNB will not cause detriment to patients (lymphoedema, morbidity, loss of quality of life) and not increase costs compared to patients without a retroperitoneal node dissection. The secondary hypothesis is that disease-free survival in patients without retroperitoneal node dissection is not inferior to those receiving SNB.
Aims: To determine the value of SNB for patients, the healthcare system and to exclude detriment to patients.
Objectives:
Primary Stage 1:
To determine the recovery of participants (defined as incidence of adverse events, lower limb lymphoedema and health-related QOL) and to the healthcare system (cost) of Sentinel Node Biopsy (SNB) for the surgical treatment of endometrial cancer.
Primary Stage 2:
Compare disease-free survival at 4.5 years for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection.
Secondary:
- Compare patterns of recurrence and overall survival (OS) between the groups
- Determine the cost-effectiveness of SNB
- Compare Patient Reported Outcomes (PROMS) between the groups at 12 months from surgery
- Compare Health Related Quality of Life (HRQL) and Fear of Recurrence between the groups at 12 months from surgery
- Compare perioperative outcomes (duration of surgery, length of hospital stay, intraoperative blood loss, blood transfusion requirements) and the incidence of intra- and postoperative adverse events within 12 months from surgery between the groups
- Compare lower limb lymphoedema at 12 months after surgery
- Compare the need for postoperative (adjuvant) treatments between groups
- Determine the impact of body composition and frailty on survival, quality of life, lymphoedema, peri-, intra- and postoperative outcomes
- Compare follow-up strategies (clinical vs symptom checklist)
- Translational Research - Trans-ENDO 3 - biobanking strategy - Compare the Molecular profile at 12 months from surgery between the groups
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前:Sara Baniahmadi
- 電話番号:+61733465073
- メール:sara.baniahmadi@health.qld.gov.au
研究連絡先のバックアップ
- 名前:Grace Ngiam
- 電話番号:+61 7 3346 5590
- メール:endo3trial@uq.edu.au
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- 募集
- Houston Methodist Hospital
-
コンタクト:
- Jaya Kamath
- 電話番号:713-441-6616
- メール:jskamath@houstonmethodist.org
-
コンタクト:
- Konny Fong
- 電話番号:346.238.5815
- メール:klchanfong@houstonmethodist.org
-
主任研究者:
- Behrouz Zand, MD
-
副調査官:
- Tarrik Zaid, MD
-
副調査官:
- Aparna Kamat, MD
-
副調査官:
- Anju Suri, MD
-
副調査官:
- Pedro Ramirez, MD
-
-
-
-
Ciudad Autónoma de Buenos Aires (caba)
-
Buenos Aires、Ciudad Autónoma de Buenos Aires (caba)、アルゼンチン
- 募集
- Hospital Italiano
-
コンタクト:
- Diego Odetto, MD
- メール:diego.odetto@hospitalitaliano.org.ar
-
主任研究者:
- Diego Odetto, MD
-
Buenos Aires、Ciudad Autónoma de Buenos Aires (caba)、アルゼンチン
- 募集
- Hospital Britanico
-
コンタクト:
- Julian Di Guilmi, MD
- メール:Jdiguilmi@hbritanico.com.ar
-
主任研究者:
- Julian Di Guilmi, MD
-
-
-
-
Via Pozzuolo
-
Udine、Via Pozzuolo、イタリア、33100
- 募集
- Azienda Sanitaria Universitaria Friuli Centrale (ASUFC)
-
コンタクト:
- Giuseppe Vizzielli, MD
- メール:giuseppe.vizzielli@asufc.sanita.fvg.it
-
副調査官:
- Stefano Restaino, MD
-
コンタクト:
- Stefano Restaino, MD
- メール:stefano.restaino@asufc.sanita.fvg.it
-
主任研究者:
- Giuseppe Vizzielli, MD
-
-
-
-
New South Wales
-
Camperdown、New South Wales、オーストラリア、2050
- 募集
- Chris O'Brien Lifehouse
-
コンタクト:
- Rhonda Farrell, MD
- メール:rhondafarrell@mac.com
-
主任研究者:
- Rhonda Farrell, MD
-
コンタクト:
- Sadaf Kalam
- メール:sadaf.kalam@lh.org.au
-
Liverpool、New South Wales、オーストラリア、2170
- 募集
- Liverpool Hospital
-
コンタクト:
- Michael Burling, MD
- メール:michael.burling@health.nsw.gov.au
-
主任研究者:
- Michael Burling, MD
-
-
Queensland
-
Auchenflower、Queensland、オーストラリア、4066
- 募集
- The Wesley Hospital
-
コンタクト:
- Sara Baniahmadi
- 電話番号:+61 7 3346 5073
- メール:sara.baniahmadi@health.qld.gov.au
-
主任研究者:
- Andrea Garrett, MD
-
副調査官:
- Rhett Morton, MD
-
コンタクト:
- Grace Ngiam
- 電話番号:+61 7 3346 5590
- メール:endo3trial@uq.edu.au
-
Brisbane、Queensland、オーストラリア、4120
- 募集
- Greenslopes Private Hospital
-
コンタクト:
- Sara Baniahmadi
- 電話番号:+61733465073
- メール:sara.baniahmadi@health.qld.gov.au
-
コンタクト:
- Grace Ngiam
- 電話番号:+61733465590
- メール:endo3trial@uq.edu.au
-
主任研究者:
- Shaun McGrath, MD
-
Buderim、Queensland、オーストラリア、4556
- 募集
- Buderim Private Hospital
-
コンタクト:
- Sara Baniahmadi
- 電話番号:+61733465073
- メール:sara.baniahmadi@health.qld.gov.au
-
主任研究者:
- Andreas Obermair, MD
-
コンタクト:
- Grace Ngiam
- 電話番号:+61 7 3346 5590
- メール:endo3trial@uq.edu.au
-
Everton Park、Queensland、オーストラリア、4053
- 募集
- North West Private Hospital
-
コンタクト:
- Sara Baniahmadi
- 電話番号:+61733465073
- メール:sara.baniahmadi@health.qld.gov.au
-
主任研究者:
- Piksi Singh, MD
-
コンタクト:
- Grace Ngiam
- 電話番号:0733465590
- メール:endo3trial@uq.edu.au
-
Herston、Queensland、オーストラリア、4029
- 募集
- Royal Brisbane and Women's Hospital
-
コンタクト:
- Sara Baniahmadi
- 電話番号:+61733465073
- メール:sara.baniahmadi@health.qld.gov.au
-
主任研究者:
- Andrea Garrett, MD
-
副調査官:
- Andreas Obermair, MD
-
副調査官:
- Russell Land, MD
-
副調査官:
- Piksi Singh, MD
-
副調査官:
- Shaun McGrath, MD
-
コンタクト:
- Grace Ngiam
- 電話番号:+61 7 3346 5590
- メール:endo3trial@uq.edu.au
-
South Brisbane、Queensland、オーストラリア、4101
- 募集
- Mater Hospital
-
コンタクト:
- Sara Baniahmadi
- 電話番号:+61733465073
- メール:sara.baniahmadi@health.qld.gov.au
-
副調査官:
- Nisha Jagasia, MD
-
副調査官:
- Nimithri Cabraal, MD
-
副調査官:
- Rhett Morton, MD
-
主任研究者:
- Naven Chetty, MD
-
コンタクト:
- Grace Ngiam
- 電話番号:+61 7 3346 5590
- メール:endo3trial@uq.edu.au
-
副調査官:
- Simon West, MD
-
Southport、Queensland、オーストラリア、4215
- まだ募集していません
- Gold Coast University Hospital
-
コンタクト:
- Sara Baniahmadi
- 電話番号:+61733465073
- メール:sara.baniahmadi@health.qld.gov.au
-
主任研究者:
- Elizabeth Goulding, MD
-
コンタクト:
- Grace Ngiam
- 電話番号:+61 7 3346 5590
- メール:endo3trial@uq.edu.au
-
Spring Hill、Queensland、オーストラリア、4000
- 募集
- St Andrews War Memorial Hospital
-
コンタクト:
- Sara Baniahmadi
- 電話番号:+61733465073
- メール:sara.baniahmadi@health.qld.gov.au
-
主任研究者:
- Andreas Obermair, MD
-
コンタクト:
- Grace Ngiam
- 電話番号:+61 7 3346 5590
- メール:endo3trial@uq.edu.au
-
-
Victoria
-
Heidelberg、Victoria、オーストラリア、3084
- 募集
- Mercy Hospital for Women
-
コンタクト:
- Adam Pendlebury, MD
- メール:cgo@dradampendlebury.com.au
-
主任研究者:
- Adam Pendlebury, MD
-
コンタクト:
- Carla Starmans
- メール:Cstarmans@mercy.com.au
-
Melbourne、Victoria、オーストラリア、3002
- 募集
- Epworth Freemasons
-
コンタクト:
- Adam Pendlebury, MD
- メール:cgo@dradampendlebury.com.au
-
主任研究者:
- Adam Pendlebury, MD
-
Parkville、Victoria、オーストラリア、3052
- 募集
- Royal Women's Hospital
-
コンタクト:
- Orla McNally, MD
- メール:Orla.McNally@thewomens.org.au
-
主任研究者:
- Orla McNally, MD
-
副調査官:
- Deborah Neesham, MD
-
コンタクト:
- Estefania Vicario
- メール:estefania.vicario@thewomens.org.au
-
-
-
-
Antioquia
-
Medellín、Antioquia、コロンビア、050025
- 募集
- Promotora Médica Las Américas S.A.
-
コンタクト:
- Gabriel Rendon, MD
- メール:gabriel.rendon@auna.org
-
主任研究者:
- Gabriel Rendon, MD
-
-
Bogotá, Distrito Capital
-
Bogotá、Bogotá, Distrito Capital、コロンビア、110131
- 募集
- Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo
-
コンタクト:
- David Viveros, MD
- メール:dviverosc@gmail.com
-
コンタクト:
- Briegal De Las Calderon
- メール:bcalderon@fctic.org
-
主任研究者:
- David Viveros, MD
-
-
-
-
NUH Zone B
-
Singapore、NUH Zone B、シンガポール、119074
- 募集
- National University Hospital and National University Cancer Institute
-
コンタクト:
- Joseph Ng Soon Yau, MD
- メール:obgnsyj@nus.edu.sg
-
コンタクト:
- Pearl S Tong, MD
- メール:pearl_sy_tong@nuhs.edu.sg
-
主任研究者:
- Joseph Ng Soon Yau, MD
-
副調査官:
- Pearl S Tong, MD
-
副調査官:
- Jeffrey Low, MD
-
副調査官:
- Jeslyn Wong, MD
-
-
-
-
São Paulo
-
São José do Rio Preto、São Paulo、ブラジル、15090-000
- 募集
- Hospital de Base
-
コンタクト:
- Guilherme Accorsi, MD
- メール:dr.guilhermeaccorsi@gmail.com
-
主任研究者:
- Guilherme Accorsi, MD
-
São Paulo、São Paulo、ブラジル
- 募集
- Fundacao Antonio Prudente, AC Camargo Cancer Center
-
コンタクト:
- Glauco Baiocchi Neto, MD
- メール:glauco.baiocchi@accamargo.org.br
-
コンタクト:
- Bruna Goncalves
- メール:bruna.goncalves@accamargo.org.br
-
主任研究者:
- Glauco Baiocchi Neto, MD
-
São Paulo、São Paulo、ブラジル
- 募集
- Hospital Israelita Albert Einstein
-
コンタクト:
- Renato Moretti-Marques, MD
- メール:morettimarques@gmail.com
-
コンタクト:
- Renato
-
主任研究者:
- Renato Moretti-Marques, MD
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Females, over 18 years, with histologically confirmed primary epithelial cancer of the endometrium of any cell type or uterine carcinosarcoma (mixed malignant mullerian tumour);
- Clinically stage I disease (disease confined to body of uterus);
- Eastern Cooperative Oncology Group (ECOG) performance status of ≤2;
- Signed written informed consent;
- Participant must meet criteria for a laparoscopic or robotic surgical approach as determined by the treating physician (e.g. suitable for TH BSO, ability to tolerate Trendelenberg positioning)
- All available clinical evidence (physical examination findings, or medical imaging such as CT, MRI or ultrasound) demonstrates no evidence of extrauterine disease
- Myometrial Invasion on MRI of not more than 50%. (Only if participant is <45yo, has ONLY Grade 1 EAC and wishes to retain their ovaries).
- Negative (serum or urine) pregnancy test ≤ 30 days of surgery in pre-menopausal women and women < 2 years after the onset of menopause.
Exclusion Criteria:
- Evidence of extrauterine disease (apparent involvement of cervix, vagina, parametria, adnexa, lymph nodes, bladder, bowel or distant sites) by clinical examination and/or through medical imaging.
- Enlarged retroperitoneal pelvic and/or aortic lymph nodes (>1 cm) on medical imaging;
- Estimated life expectancy of less than 6 months;
- Patients who have absolute contraindications for adjuvant radiotherapy and/or chemotherapy;
- Patients who have previously received radiation treatment to the pelvis
- Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator);
- Patient compliance and geographic proximity that do not allow adequate follow-up;
- Patients with allergy to Indocyanine Green (ICG)
- Patients who have had previous retroperitoneal surgery
- Patients who require a retroperitoneal (pelvic +/- para-aortic) lymph node dissection (lymphadenectomy)
- Other prior malignancies <5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma of the breast insitu
- Uterine perforation during endometrial tissue sampling
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:TH BSO with SNB
Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG)+/- Methylene Blue Dye (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted. |
Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) +/- Methylene Blue Dye is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the "sentinel node". These one or two nodes are thought to be first involved with cancer spread. |
|
アクティブコンパレータ:TH BSO without retroperitoneal node dissection
Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted. |
Removal of uterus, tubes and ovaries without retroperitoneal node dissection |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Stage 1: Return to usual activities
時間枠:12 months from surgery
|
Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities. |
12 months from surgery
|
|
Stage 2: Disease Free Survival
時間枠:4.5 years from surgery
|
Compare disease-free survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection |
4.5 years from surgery
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Cost Effectiveness using QALYs using EuroQoL-5D (EQ-5D) Questionnaire
時間枠:12 months from surgery
|
An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life. We will also measure the quality-adjusted life years (QALYs) gained with the intervention and use this to undertake a cost-utility analysis. The QALY calculations will be based on health status measures for trial participants, with valuations of changes in health status and quality of life based on the EQ-5D |
12 months from surgery
|
|
Cost Effectiveness measuring Intervention costs
時間枠:12 months from surgery
|
An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society. |
12 months from surgery
|
|
Cost Effectiveness measuring GP and specialist consultations
時間枠:12 months from surgery
|
An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life. |
12 months from surgery
|
|
Cost Effectiveness measuring radiology and imaging requirements
時間枠:12 months from surgery
|
An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society. |
12 months from surgery
|
|
Cost Effectiveness measuring prescriptions and over the counter medicine requirements
時間枠:12 months from surgery
|
An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life. |
12 months from surgery
|
|
Cost Effectiveness measuring community and health service requirements and days off work and informal care required by family and friends using a combination of the Health Services Questionnaire and clinical files
時間枠:12 months from surgery
|
An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life. |
12 months from surgery
|
|
Cost Effectiveness: direct costs using a bottom-up approach by recording the volume of resource use in both groups of the trial, and then applying a unit cost to each component
時間枠:12 months from surgery
|
Direct costs wukk be ibtained for smaples of participants, stratified by hospital, operation and outcome to assess the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society. |
12 months from surgery
|
|
Perioperative Outcomes: Adverse Events
時間枠:12 months from surgery
|
Compare perioperative outcomes and the incidence of intra- and postoperative adverse events within 12 months from surgery between groups using Common Terminology Criteria for Adverse Events (CTCAE version 5) |
12 months from surgery
|
|
Perioperative Outcomes: Length of Surgery
時間枠:At time of surgery
|
Compare the length of surgery between the two groups. This will be recorded in hh:mm on the surgery form. |
At time of surgery
|
|
Perioperative Outcomes: Blood Loss during Surgery
時間枠:At time of surgery
|
Compare the blood loss between the two groups during surgery. This will be recorded in ml. |
At time of surgery
|
|
Perioperative Outcomes: Blood Transfusion Requirements during Surgery
時間枠:At time of surgery
|
Compare the blood transfusion requirements between the two groups. This will be recorded in units and recorded on the Surgery Form and the Concomitant Medication Form. |
At time of surgery
|
|
Perioperative Outcomes: Length of Hospital Stay
時間枠:At time of discharge from hospital following surgery
|
Compare the length of hospital stay between the two groups. The duration will be measured in days. Date of surgery being day 0. |
At time of discharge from hospital following surgery
|
|
Health Related Quality of Life and Fear of Recurrence
時間枠:12 months from surgery
|
Change in Quality of Life using Functional Assessment of Cancer General (FACT-EN), Fear of Recurrence and PROMS between baseline and 1 year after surgery |
12 months from surgery
|
|
Incidence of Lymphedema
時間枠:12 months from surgery
|
Compare lower limb lymphedema between groups |
12 months from surgery
|
|
Adjuvant Treatment Requirements
時間枠:12 months from surgery
|
Compare the need for postoperative (adjuvant) treatments between groups and evaluate the impact of SNB on clinical decisions regarding adjuvant treatment. Any chemotherapy or radiation therapy required will be recorded on specific chemotherapy or radiation forms. Chemotherapy will be recorded in mg received and number of doses required including start/end dates. Radiation treatment received will be recorded as total dose of Gy and how many fractions, including start and end dates. |
12 months from surgery
|
|
Value of Molecular Biomarkers
時間枠:24 months from surgery
|
Translational Research - Compare Molecular profile from surgery between the groups that require adjuvant therapy for 24 months. |
24 months from surgery
|
|
Value of Molecular Biomarkers
時間枠:12 months from surgery
|
Translational Research - Compare the Molecular profile of Germline DNA at 12 months from surgery between the groups |
12 months from surgery
|
|
Value of Molecular Biomarkers
時間枠:12 months from surgery
|
Translational Research - Compare the Molecular profile of Circulating Tumour DNA at 12 months from surgery between the groups |
12 months from surgery
|
|
Value of Molecular Biomarkers
時間枠:12 months from surgery
|
Translational Research - Compare the Molecular profile of Plasma at 12 months from surgery between the groups |
12 months from surgery
|
|
Value of Molecular Biomarkers
時間枠:12 months from surgery
|
Translational Research - Compare the Molecular profile of Serum at 12 months from surgery between the groups |
12 months from surgery
|
|
Overall Survival
時間枠:4.5 years from surgery
|
Compare overall survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection |
4.5 years from surgery
|
|
Patterns of Recurrence - date and localization of 1st recurrence
時間枠:4.5 years from surgery
|
Date and localization of 1st recurrence as confirmed histologically and/or radiologically - Compare these patterns of recurrences between the groups. These will also be adjudicated by an independent committee to ensure accuracy of documented recurrence |
4.5 years from surgery
|
|
Impact of body composition (sarcopenia) on surgical complications, recovery and overall survival
時間枠:4.5 years from surgery
|
Body mass measures are practical & sensitive for predicting health risks & outcomes. Sarcopenia is defined as loss of skeletal muscle mass & strength. It's been found to be associated with procedure-related morbidity, survival in cancer patients and increased use of healthcare. The concurrent appearance of low muscle mass with high adiposity (sarcopenic obesity) is common in people with chronic diseases. The trial will determine the role sarcopenia has on participants pre-operatively (via CT images & Bioimpedance Spectroscopy (BIS - if available at site) & postoperatively using the BIS in regard to survival in gynaecological malignancies, if it is a predictive factor for treatment adverse events & participants tolerability of treatment & compare diagnostic methods to determine medical fitness for surgery. BIS sends non-detectable electrical currents, at a range of frequencies through the body allowing precise measurement & analysis of impedance to currents by extracellular fluid |
4.5 years from surgery
|
|
Impact of frailty on surgical complications, recovery and overall survival
時間枠:4.5 years from surgery
|
It has been reported consistently that frailty has a significant impact on the occurrence of adverse postoperative outcomes. Therefore, measuring frailty is important to estimate risks, determine the best treatment options, and to aid diagnosis and care planning. Frailty will be measured prior to surgery suing the validated tool - Frailty Phenotype. This may determine the impact frailty has on survival, quality of life, lymphedema, peri-, intra- and postoperative outcomes |
4.5 years from surgery
|
|
Follow-Up Strategies
時間枠:4.5 years from surgery
|
Current institutional & clinical guidelines suggest patients need to be seen at regular follow up visits. The risk of developing a recurrence is higher within the initial period after surgery & the majority of recurrences develop within those first 3 years. Participants will ideally be seen 3 monthly for the first 3 years & 6 monthly until 4.5 years. The objective of follow up is that local recurrences from endometrial cancer are potentially curable. It helps to diagnose local recurrences as early as possible so that they are amenable for curative or effective palliative management. We will compare these clinical findings to a symptom checklist that will be completed by participants every 3 months from surgery until 4.5 years. This records patient reported symptoms that may indicate a recurrence. Comparing these findings should determine effective follow up strategies for this group of patients. |
4.5 years from surgery
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- スタディチェア:Andreas Obermair, Prof、Director, Queensland Centre for Gynaecological Cancer Research
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- ENDO-3
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。